Temozolomide and stenoparib for relapsed small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests two drugs—temozolomide and stenoparib—for people with small cell lung cancer that has returned after initial chemo. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You have extensive-stage small cell lung cancer that has spread.
- You have already had carboplatin and etoposide chemotherapy as your first treatment.
- Your daily activity level is fairly good (ECOG score 0-2).
- Your major organs (bone marrow, liver, kidneys) need to be working well enough, as shown by blood tests.
- If you are able to become pregnant, you must not be pregnant and must use birth control during and for 180 days after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a new drug combination (lurbinectedin with or without irinotecan) against the standard treatment (topotecan) for people whose small cell lung cancer has come back after initial chemotherapy. It aims to see if the new options work better.
This trial tests a new drug, NMS-03305293, in adults with small cell lung cancer that has come back after earlier treatments. The goal is to see if it can help shrink or slow the cancer.
This trial tests different treatments based on the genetic and molecular features of your tumor. It is for people with stage IV small cell lung cancer that has returned after initial chemotherapy.
This trial studies temozolomide plus atezolizumab in people with metastatic or recurring small cell lung cancer that has already come back or progressed after standard platinum chemotherapy plus immunotherapy. It may help by trying a new combination after prior treatment has stopped working.
This study tests a new drug (GSK5764227) for people whose extensive-stage small cell lung cancer has gotten worse after platinum chemotherapy combined with immunotherapy. The goal is to see if this targeted treatment can help shrink tumors and control the cancer.
This trial tests a combination of a second course of chemotherapy and an immunotherapy drug (atezolizumab) for people with extensive-stage small cell lung cancer that has returned after initial treatment. The goal is to see if re-using these treatments together can help control the cancer again.
Hear when a new Relapsed Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.